MX384909B - Un anticuerpo anti-tau para usarse al tratar una tauopatía. - Google Patents

Un anticuerpo anti-tau para usarse al tratar una tauopatía.

Info

Publication number
MX384909B
MX384909B MX2016006356A MX2016006356A MX384909B MX 384909 B MX384909 B MX 384909B MX 2016006356 A MX2016006356 A MX 2016006356A MX 2016006356 A MX2016006356 A MX 2016006356A MX 384909 B MX384909 B MX 384909B
Authority
MX
Mexico
Prior art keywords
tau antibody
individual
treating
tauopathy
treating tauopathy
Prior art date
Application number
MX2016006356A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006356A (es
Inventor
Graham Parry
Irene Griswold-Prenner
Original Assignee
Ipierian Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipierian Inc filed Critical Ipierian Inc
Publication of MX2016006356A publication Critical patent/MX2016006356A/es
Publication of MX384909B publication Critical patent/MX384909B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2016006356A 2013-11-27 2014-11-25 Un anticuerpo anti-tau para usarse al tratar una tauopatía. MX384909B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361909965P 2013-11-27 2013-11-27
PCT/US2014/067360 WO2015081085A2 (en) 2013-11-27 2014-11-25 Methods of treating a tauopathy

Publications (2)

Publication Number Publication Date
MX2016006356A MX2016006356A (es) 2016-10-28
MX384909B true MX384909B (es) 2025-03-14

Family

ID=52232410

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006356A MX384909B (es) 2013-11-27 2014-11-25 Un anticuerpo anti-tau para usarse al tratar una tauopatía.
MX2021008755A MX2021008755A (es) 2013-11-27 2016-05-16 Un anticuerpo anti-tau para usarse al tratar una tauopatia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008755A MX2021008755A (es) 2013-11-27 2016-05-16 Un anticuerpo anti-tau para usarse al tratar una tauopatia.

Country Status (9)

Country Link
US (2) US20160289309A1 (enExample)
EP (1) EP3074420A2 (enExample)
JP (1) JP6629201B2 (enExample)
CN (2) CN105899230B (enExample)
BR (1) BR112016010454A2 (enExample)
CA (1) CA2931396C (enExample)
EA (1) EA038994B1 (enExample)
MX (2) MX384909B (enExample)
WO (1) WO2015081085A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035976B1 (ru) * 2012-08-16 2020-09-08 АйПИЕРИАН, ИНК. Анти-tau антитела для лечения таупатий
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
WO2017100632A1 (en) * 2015-12-11 2017-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2018231254A1 (en) * 2017-06-16 2018-12-20 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
US20190135905A1 (en) * 2017-06-16 2019-05-09 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
GB202010652D0 (en) * 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
CN115607684A (zh) * 2021-07-15 2023-01-17 华中科技大学 一种内耳药物纳米载体及其应用
KR20240118915A (ko) * 2021-11-03 2024-08-05 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 조성물, 투여 형태 및 방법
WO2025196217A1 (en) * 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
WO1996019487A1 (en) 1994-12-22 1996-06-27 Nissan Chemical Industries, Ltd. Organobismuth derivatives and process for producing the same
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
CA2313225A1 (en) 1997-12-12 1999-06-17 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP2012510798A (ja) 2008-12-05 2012-05-17 アンジオケム インコーポレーテッド ペプチド治療剤コンジュゲートおよびその使用
CA3120504A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011026031A1 (en) * 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
BR112012010587A2 (pt) * 2009-11-06 2015-09-29 David Gladstone Inst métodos e composições para modulação de níveis de tau.
BR112013008333B1 (pt) * 2010-10-07 2022-10-11 Ac Immune S.A. Anticorpo, composição farmacêutica, hibridoma, polinucleotídeo, método de diagnóstico in vitro e usos do anticorpo
MX345092B (es) * 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN109265543B (zh) * 2011-09-19 2022-04-26 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
EA035976B1 (ru) * 2012-08-16 2020-09-08 АйПИЕРИАН, ИНК. Анти-tau антитела для лечения таупатий

Also Published As

Publication number Publication date
EP3074420A2 (en) 2016-10-05
BR112016010454A2 (pt) 2017-12-05
US20160289309A1 (en) 2016-10-06
JP6629201B2 (ja) 2020-01-15
MX2016006356A (es) 2016-10-28
CN105899230B (zh) 2020-06-09
US20200102375A1 (en) 2020-04-02
CN111569063A (zh) 2020-08-25
CA2931396A1 (en) 2015-06-04
JP2017504570A (ja) 2017-02-09
WO2015081085A2 (en) 2015-06-04
EA201690898A1 (ru) 2016-09-30
EA038994B1 (ru) 2021-11-18
WO2015081085A3 (en) 2015-08-06
MX2021008755A (es) 2021-08-24
CN105899230A (zh) 2016-08-24
CA2931396C (en) 2022-09-06

Similar Documents

Publication Publication Date Title
MX384909B (es) Un anticuerpo anti-tau para usarse al tratar una tauopatía.
UY40476A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
EA201792613A1 (ru) Модуляторы cot и способы их применения
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
ECSP16081503A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
PH12015500196B1 (en) Methods of treating a tauopathy
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
MX2016005956A (es) Anticuerpos especificos para fcrn.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
BR112016008458A2 (pt) embalagem de cápsulas de uso único, máquina para embalar e método para embalar
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
MX2015016305A (es) Biomarcador predictivo para terapia contra el cancer.
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX2016002308A (es) Tratamiento del mieloma multiple.
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии